<DOC>
	<DOCNO>NCT00770913</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety E3810 tablets patient Proton Pump Inhibitor-resistant reflux esophagitis .</brief_summary>
	<brief_title>Double-blind Comparative Study E3810 Tablets ( 10 20 mg b.i.d . ) Evaluate Efficacy Safety Patients With Refractory Reflux Esophagitis</brief_title>
	<detailed_description>This multicenter , randomize , double-blinded study . The efficacy E3810 20 mg daily compare E3810 20 mg twice daily 10 mg twice daily use endoscopic recovery . The frequency adverse event , etc. , compare among 3 group safety assessment .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Patients mucosal break ( erosion , ulcer ) endoscopy diagnose reflux esophagitis . Proton Pump Inhibitor standard doseresistant reflux esophagitis . Patients 20 year old informed consent obtain . Patients concurrent severe illness , serious heart disease , comorbid severe disease hematology , kidney disease , liver disease . Patients malignancy . Patients take another trial drug interval end treatment screen less 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>reflux esophagitis</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>GERD</keyword>
	<keyword>Japan</keyword>
</DOC>